gms | German Medical Science

16. Deutscher Kongress für Versorgungsforschung

Deutsches Netzwerk Versorgungsforschung e. V.

4. - 6. Oktober 2017, Berlin

Drug interactions in community-dwelling people screened positive for dementia: Data from the DelpHi study

Meeting Abstract

  • Diana Wucherer - Deutsches Zentrum für neurodegenerative Erkrankungen (DZNE) e.V., Greifswald, Germany
  • Jochen René Thyrian - Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Greifswald, Germany
  • Johannes Hertel - Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universitätsmedizin Greifswald, Greifswald, Germany
  • Bernhard Norbert Michalowsky - Deutsches Zentrum für neurodegenerative Erkrankungen (DZNE) e.V., Standort Rostock/Greifswald, Greifswald, Germany
  • Ina Zwingmann - Deutsches Zentrum für neurodegenerative Erkrankungen (DZNE) e.V., Standort Rostock/Greifswald, Greifswald, Germany
  • Wolfgang Hoffmann - Universitätsmedizin Greifswald, Greifswald, Germany

16. Deutscher Kongress für Versorgungsforschung (DKVF). Berlin, 04.-06.10.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocV095

doi: 10.3205/17dkvf163, urn:nbn:de:0183-17dkvf1636

Veröffentlicht: 26. September 2017

© 2017 Wucherer et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Background: Approximately 75% of the 1.5 million people with dementia in Germany are community-dwelling patients. Most of them are affected by multiple chronic diseases and are treated with complex pharmacotherapy regimes that are associated with drug interactions. However, little is known about the prevalence of drug interactions in community-dwelling people screened positive for dementia.

Objectives: This analysis aimed to determine (1) the active agent - related prevalence of drug interactions and (2) the socio-demographic and clinical variables associated with total number of drug interactions in community-dwelling people screened positive for dementia.

Methods: The DelpHi-MV study (Dementia: life- and person-centered help in Mecklenburg - Western Pomerania) is a general practitioner (GP)-based cluster-randomized controlled intervention trial to implement and evaluate an innovative concept of collaborative dementia care management in the primary care setting in Germany. Medication reviews of n=446 study participants were conducted by pharmacists based on the comprehensive baseline assessment that included a computer-based home medication assessment.

Results: Of the n=446 patients, a total of 155 (35%) had at least one potential drug interaction of moderate severity, 14 (3%) had at least one clinically relevant drug interaction, and 11 (2%) had at least one inappropriate combination of drugs with food. Total number of drugs taken (OR 1.26) and support with medication (OR 2.09) were associated with drug interactions.

Discussion: The most frequent specific drug interactions will be presented and discussed. The present analysis underlined that a comprehensive medication review has the potential to improve the pharmacotherapy in community-dwelling people living with dementia is of major importance.